RECALL ALERT: Blood Pressure Pills At Risk

Yellow sticky note with the word 'RECALL' on a corkboard — Photo: Bankrx / Shutterstock

A common blood pressure pill was recalled twice in three months because it may not dissolve or work as intended.

Story Snapshot

Inventia Healthcare recalled chlorthalidone 25 mg tablets nationwide due to failed dissolution tests.
First recall began June 5 for 11,460 bottles; a second on Sept. 3 covered 13,567 bottles.
Food and Drug Administration (FDA) classified the September action as a Class II recall on Sept. 17.
No injuries had been reported when news outlets covered the recall.

What Was Recalled, When, and Why It Matters

Inventia Healthcare Limited initiated two recalls of chlorthalidone tablets, United States Pharmacopeia, 25 milligrams, that were distributed across the United States. The drug is a diuretic that helps lower blood pressure. Company testing showed some tablets did not meet dissolution standards.

That means the pill may not break down as expected after you swallow it, which can reduce how well it lowers blood pressure. Lower effect can leave patients with readings that stay too high until they switch lots or refill.

The first action began June 5, 2026, and covered 11,460 bottles in commerce, according to recall summaries. Those reports tie the recall to failed dissolution specifications during quality testing. A second and larger action began Sept. 3, 2026, for 13,567 bottles after the same type of failure.

Reports identify the September units as 100-count bottles from lot RISA24002 with an April 2027 expiration date. News coverage at the time said no injuries had been reported.

FDA Classification and What Class II Really Means

The Food and Drug Administration classified the September recall as Class II on Sept. 17. Here is what it means in plain terms. Class II covers products that could cause temporary or medically reversible health effects, with a remote chance of serious harm.

The agency uses this class for quality defects that may blunt a drug’s effect, like slow or uneven dissolution, but do not suggest acute toxicity or contamination.

Widely used blood pressure medication recalled nationwide https://t.co/Y3YjWnZsOZ #FoxBusiness

— Greg Shields (@GregShield83077) September 30, 2026

For patients, the practical risk is loss of blood pressure control. That can show up as headaches, dizziness, or higher readings at home. Doctors do not want patients to stop medicine without a plan.

The safer path is to check the bottle’s lot number, call the pharmacy, and ask for a replacement from a different lot. Pharmacists can process a recall return and dispense an unaffected supply. This treats the quality issue without risking a sudden jump in blood pressure.

Scope, Identification, and How to Check Your Supply

Reports state the recall is nationwide and involves chlorthalidone 25 milligram tablets in 100-count bottles, with some earlier reports also mentioning 1,000-count bottles in the June action. The September lot widely cited is RISA24002, expiring April 2027. Labels may show Inventia Healthcare as the manufacturer.

If your bottle matches the drug name, strength, and count, check the lot code and expiration on the side panel. If you’re unsure, ask your pharmacist to verify it against the recall notice.

🚨 FDA Drug Recall

Inventia Healthcare is recalling 13,567 bottles of 25 mg chlorthalidone tablets after the batch failed dissolution specifications.

Batch: RISA24002
Expiration: April 2027

Read More: https://t.co/5im9lRvIZO #FDA #Recall #Chlorthalidone pic.twitter.com/Ow089zG68j

— Global News (@GlobalNews1126) September 29, 2026

Consumers should monitor their blood pressure and symptoms. If readings creep up and you use a recalled lot, call your clinician. Do not double your dose to “make up” for a weak tablet.

The dose-response for blood pressure drugs isn’t linear, and guessing at potency isn’t safe. Pharmacies can swap the lot for you. If you threw out the box, bring the bottle; the pharmacist can still check the code in their system.

Why Dissolution Failures Keep Showing Up in Recalls

Dissolution sits at the bridge between chemistry and clinical effect. A tablet can look fine, pass identity tests, and still fail to deliver the drug at the right speed if the formula or process drifts.

Regulators expect tight control of granulation, compression force, and coatings. When those vary, patients may get less drug over time. That is why FDA actions like this one land as Class II: the concern is reduced effect, not poison in the bottle.

Quality systems exist to catch problems before patients do. Two recalls in a summer should prompt stronger oversight and faster fixes. That is not overreach; it is basic stewardship. Patients deserve pills that work the same every time, no matter the labeler or lot.

The facts align with a clear standard: test well, publish clearly, correct fast, and keep medicine reliable at scale. That protects lives and respects the trust we place at the pharmacy counter.